DMK Pharmaceuticals Regains Full Rights from US WorldMeds for SYMJEPI® and Provides Corporate Update
November 28, 2023 08:05 ET
|
DMK Pharmaceuticals Corporation
SAN DIEGO, Nov. 28, 2023 (GLOBE NEWSWIRE) -- DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial stage neuro-biotech company primarily focused on developing and commercializing products for...
Adamis Pharmaceuticals Participated in White House Meeting Regarding Opioid Overdose Prevention
June 22, 2023 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 22, 2023 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company, today announced that Eboo Versi, MD, PhD, CEO of Adamis...
Adamis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 14, 2022 16:10 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing...
US WorldMeds Launches ZIMHIDirect.com
July 05, 2022 11:32 ET
|
US WorldMeds
LOUISVILLE, Ky., July 05, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds) announces ZIMHI™ (naloxone HCL Injection) 5mg/0.5mL is now available for ordering by public interest groups through the...
Adamis Pharmaceuticals Provides Update on Clinical Study Assessing Tempol for the Treatment of COVID-19
June 01, 2022 08:00 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
March 31, 2022 16:14 ET
|
Adamis Pharmaceuticals Corporation
LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and...
Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
March 04, 2022 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 04, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the retirement of Richard C. Williams, effective April 15, 2022. “Dick has...
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
December 01, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 22, 2021 16:47 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Receives FDA Approval for ZIMHI
October 18, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced that the U.S. Food and Drug Administration (FDA) has approved Adamis’ ZIMHI™ (naloxone...